Krka, d. d. (LJSE:KRKG)

Slovenia flag Slovenia · Delayed Price · Currency is EUR
243.50
-0.50 (-0.20%)
At close: Apr 28, 2026
39.94%
Market Cap 7.38B
Revenue (ttm) 2.04B
Net Income (ttm) 403.24M
Shares Out 30.31M
EPS (ttm) 13.21
PE Ratio 18.43
Forward PE 18.57
Dividend 8.25 (3.38%)
Ex-Dividend Date Jul 21, 2026
Volume 1,876
Average Volume 3,731
Open 241.00
Previous Close 244.00
Day's Range 240.00 - 244.00
52-Week Range 173.50 - 251.00
Beta 0.46
RSI 64.71
Earnings Date May 14, 2026

About Krka, d. d.

Krka, d. d., a generic pharmaceutical company, develops, produces, markets, and sells prescription pharmaceuticals, non-prescription products, and animal health products in Slovenia, South-East Europe, East Europe, Central Europe, West Europe, and internationally. The company offers prescription pharmaceuticals for cardiovascular, central nervous system, gastrointestinal tract, pain, diabetes, and other therapeutic areas. It also provides non-prescription products for cough, cold, cerebral, peripheral circulation, gastrointestinal tract, metabo... [Read more]

Industry Pharmaceutical Preparations
Founded 1954
Employees 11,667
Stock Exchange Ljubljana Stock Exchange
Ticker Symbol KRKG
Full Company Profile

Financial Performance

In 2025, Krka, d. d.'s revenue was 2.04 billion, an increase of 6.89% compared to the previous year's 1.91 billion. Earnings were 403.24 million, an increase of 12.96%.

Financial Statements

News

Krka, d. d. Earnings Call Transcript: Q4 2025

Record revenue and net profit were achieved in 2025, driven by strong growth across key markets and product launches. The outlook for 2026 projects continued sales and profit growth, with increased investment in capacity and innovation.

3 months ago - Transcripts